Moreover, the Guidelines Development Group of the European Commission Initiative on Breast Cancer recently prioritized a clinical question on the use of multigene test to guide the use of adjuvant chemotherapy in ER + , HER2 − , and lymph node–negative or up to 3 lymph node–positive invasive breast cancer [17]. This evidence concerns the gene ESR1 and breast carcinoma.